Valuation : Alamar Biosciences, Inc.

Market Cap 2.04B 1.76B 1.65B 1.51B 2.83B 193B 2.85B 19.54B 7.61B 98.36B 7.65B 7.48B 326B P/E 2026 *
-24.1x
P/E 2027 * -42.4x
Enterprise Value 1.85B 1.6B 1.5B 1.37B 2.57B 176B 2.59B 17.74B 6.91B 89.3B 6.94B 6.79B 296B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 11.4x
Free-Float
78.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.78%
1 week-13.35%
Current month-3.31%
1 month+9.09%
3 months+41.97%
1 week 29.15
Extreme 29.15
34.98
1 month 24.85
Extreme 24.85
38.54
Current year 18.84
Extreme 18.845
38.54
1 year 18.84
Extreme 18.845
38.54
3 years 18.84
Extreme 18.845
38.54
5 years 18.84
Extreme 18.845
38.54
10 years 18.84
Extreme 18.845
38.54
Manager TitleAgeSince
Chief Operating Officer 63 01/08/2018
Chief Tech/Sci/R&D Officer - 01/01/2021
Chief Executive Officer 62 01/07/2018
Director TitleAgeSince
Chairman 62 01/07/2018
Director/Board Member 64 01/05/2020
Director/Board Member 66 28/08/2026
Date Insider Type Main position Quantity % Market Cap. Importance
20/4/26 Others

Director

206,781 --
20/4/26 Others

Director

206,781 7.4927%
20/4/26 Others

Director

140,612 5.0951%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-13.35% - - 2.04B
+0.90%-4.03%+24.75%+12.21% 222B
+1.29%-2.29%+3.26%-19.33% 145B
+3.33%+2.43%-19.12%+23.31% 130B
+3.15%+1.52%-54.15%-8.26% 69.68B
+1.31%+0.83%+11.94%+20.48% 52.3B
+0.25%+0.46%-14.74%-13.45% 50.71B
+0.98%-2.36%+20.94%+27.54% 42.28B
+1.24%-0.56%+38.91%+49.02% 39.87B
+1.63%-0.15%-13.16%+52.93% 33.37B
Average +1.49%-2.22%-0.15%+16.05% 78.82B
Weighted average by Cap. +1.61%-1.61%+2.01%+9.72%

Financials

2026 *2027 *
Net sales 119M 102M 96.22M 87.66M 165M 11.25B 166M 1.14B 443M 5.72B 445M 436M 18.98B 166M 143M 134M 122M 230M 15.73B 232M 1.59B 619M 8B 622M 609M 26.53B
Net income -64.94M -56.02M -52.69M -48M -90.27M -6.16B -90.76M -623M -242M -3.14B -244M -239M -10.4B -49.86M -43.01M -40.46M -36.86M -69.31M -4.73B -69.69M -478M -186M -2.41B -187M -183M -7.98B
Net Debt -188M -162M -152M -139M -261M -17.81B -262M -1.8B -701M -9.06B -705M -689M -30.04B -156M -134M -127M -115M -217M -14.8B -218M -1.5B -582M -7.53B -585M -573M -24.96B
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
286
Date Price Change Volume
02/09/26 US$29.53 +0.58% 54,070
01/09/26 US$29.36 -3.86% 185,086
31/08/26 US$30.54 -0.55% 325,924
28/08/26 US$30.71 -6.94% 267,641
27/08/26 US$33.00 -3.17% 281,360
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.36USD
Average target price
33.40USD
Spread / Average Target
+13.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMR Stock